Healthcare

Bringing allogeneic cell therapies to market: what Ryoncil™’s partnership models and manufacturing breakthroughs are teaching the ecosystem

Published on 23 April 2026 Read 25 min

allogeneic cell therapies agency consulting consultancy experts

Regenerative cell therapies repair damaged tissue using living cells. There are two main ways of sourcing these treatments: autologous approaches, which use the patient’s own cells, and donor-derived allogeneic methods. Autologous approaches demand significant effort and strict timing across cell collection, manufacturing, and delivery. Instead, allogeneic cell therapies open the door to scalable, off-the-shelf solutions. While appealing on paper, manufacturing challenges have historically held back their commercial viability until recent advances.

Ryoncil™ as a milestone for the field. Approved in December 2024, Mesoblast’s remestemcel (Ryoncil™) became the first FDA-approved allogeneic mesenchymal stromal cell (MSC) therapy in the US. Earlier submissions failed over concerns about batch inconsistency and insufficient efficacy data. Eighteen months post-approval and one year into commercialization, Ryoncil™ teaches the field hard-won lessons about partnerships, manufacturing, and scaling strategy. Its FDA authorization is a strong signal that the allogeneic MSC model can hold up to regulatory scrutiny.

In this article, we deep-dive in two critical factors behind Ryoncil’s™ regulatory success: strategic partnerships that enabled development at each stage, and manufacturing innovations that addressed the FDA’s primary barriers to approval.

A multi-stage partnership journey

Ryoncil’s™ journey is one of successive partnerships, each critical at key development stages. In 1993, the technology for isolating human MSCs from adult bone marrow was transferred from Case Western Reserve University to Osiris Therapeutics for commercial scaling. Through a partnership with Novartis, the asset moved through clinical trials but struggled at Phase III. In 2013, Mesoblast acquired Osiris’ stem cell portfolio and partnered with Lonza Pharma & Biotech in 2019 for commercial manufacturing to ultimately achieve Ryoncil’s™ FDA authorization¹. From then on, Mesoblast continued collaborating. In 2025, they partnered with the Blood and Marrow Clinical Trials Network, supporting patient identification to expand Ryoncil’s™ reach to the adult market by a collaborative Phase III trial². All in all, these partnerships reduced chances of late-stage failure and enabled broader distribution.

Strategic partnerships: building from lab to market

Research partnerships for patient identification and access

In the wake of Ryoncil’s story, strong academic-industrial partnerships aid development of new therapies while helping manufacturers reach target populations. For example, Thermo Fisher Scientific partnered with the University of California, San Francisco to form a cell therapy collaboration center. This center promotes cell therapy manufacturing and development, giving biotechs and large pharma companies direct access to Thermo Fisher’s cell therapy tools while encouraging easy access to cell therapies for patients of UCSF Medical Center ³⁴. Similarly, Toulouse University Hospital and Cell-Easy collaborated in the AMUSE Phase I/II Trials for the MSC treatment of Systemic Sclerosis⁵. These partnerships, like the one of Mesoblast and the Blood and Marrow Clinical Trials network, support streamlining patient identification and enrollment.

Manufacturing alliances for industrial scaling

Manufacturing partnerships are essential for scaling allogeneic therapies, as by Mesoblast with Lonza. Following this same model, as of 2022, the cell therapy manufacturer Cytiva partnered with Bayer to develop a closed allogeneic therapy manufacturing platform. Through this collaboration, Bayer’s process development experience was joined with Cytiva’s technology and consumables expertise to bring a new production approach to industrial scale. Similarly, the acquisition of Poseida Therapeutics by Roche in 2024, provided a platform for off-the-shelf CAR-T therapies⁶. As more allogeneic therapy producers have ventured towards FDA approval, partnerships with larger organizations have become critical for scaling

In the end, the allogenic field has been growing into a partnership-driven ecosystem, one that brings together biotech innovation and industrial execution.

Manufacturing at scale: best practices to overcome regulator’s biggest barrier

CMC and process challenges: bridging the gap between process validation and scale-up

Once a process is proven, operational reality becomes the major risk for scaling up products. Although Phase III data was enough for FDA acceptance of Ryoncil™, the 2023 resubmission still had to address CMC (Chemistry, Manufacturing, and Controls) concerns left over from its 2020 rejection. At the same time, three other regenerative cell products — EB-101, CAP-1002, and an allogeneic EBV-specific T-cell therapy — were rejected over CMC concerns or efficacy concerns. Ryoncil’s™ approval showed these hurdles could be cleared notably by identifying unique measures of success and reducing risk through optimized culturing practices, serving as a proof of concept for others⁷.

Proving efficacy: tying potency markers to patient outcomes

Demonstrating homogeneity and potency across batches is the defining challenge for FDA approval, and it was Ryoncil’s™ central stumbling block in earlier submissions. Many MSC producers struggle with variability between approaches, donor heterogeneity, and subpar culture practices leading to low potency⁸. In the case of Ryoncil™, the FDA asked Mesoblast to dig into its Phase III dataset and identify biomarker signals that could tie the potency assay to real patient outcomes. By using clinically relevant biomarker scores (i.e. suppression of IL-2Rα expression on T-cells) and comparing against a larger control group, Mesoblast demonstrated its product’s activity rather than relying on generic markers that had failed in Ryoncil’s™ earlier submissions.⁹¹⁰¹¹¹²¹³

Learning from Mesoblast’s FDA approval experience, some developers like Cytiva and Bayer are now investing more in assay development to link unique potency markers to clinical endpoints. This trend is relevant for markets outside of FDA jurisdiction as well. Internationally, two induced pluripotent stem cell treatments (ReHeart® and Amchepry®) were conditionally authorized in Japan in February of 2026, contingent on additional proof of safety and efficacy in coming years¹⁴. Ryoncil, like these treatments, struggled to initially prove efficacy, but through a combination of appropriate marker types and control data, was able to secure approval. By establishing a clear link between potency markers and clinical outcomes, Ryoncil™ showed the field one way of making it through FDA approval, which could help other groups make their own way to acceptance.

Automation and closed systems: building consistency at scale

Since consistent manufacturing is critical for high efficacy allogenic products, developers including Lonza, Mesoblast, Bayer, and Cytiva have invested in 3D bioreactors and process automation as their next major steps forward. These approaches are expected to increase batch sizes without sacrificing consistency, reducing human dependency in manufacturing systems, and tackling the reproducibility problems that have kept so many cell therapies from reaching the market. Allogenic medicine is pointed away from labor-intensive, open processes and is heading toward closed, automated, digitally monitored systems that can sustain commercial supply. Here too, the broader field appears to be internalizing Ryoncil’s™ experience. Closed manufacturing platforms are increasingly regarded as the standard for new allogeneic programs.

Ryoncil’s™ FDA approval was a landmark for allogeneic medicine, both validating the MSC approach for allogenic therapies and giving future developers a concrete roadmap to build on. It makes clear how much strategic partnerships matter, from academic research to commercial manufacturing, while also highlighting the CMC and potency-testing challenges that others will navigate. The field is beginning to act on these lessons through cleaner assay development, closed manufacturing platforms, and the formation of industrial alliances.

What remains to be seen is whether these learnings will be adopted broadly and translate into a faster, more predictable approval pathway for the next generation of allogeneic therapies, or whether each program will need to rediscover these lessons for their unique context. At Alcimed, we will continue to follow developments in this field. Do not hesitate to contact our team.

About the author,

Julianna, Consultant in Alcimed’s Life Sciences team in the USA

Have a project and want to discuss it?

To go further

Healthcare

4 key facts steering the future direction of CAR T-Cell therapies

CAR T-cell therapies gain more and more attention as being innovative immunotherapy options for cancer patients. Although being researched for years, the approval reach of new treatments is yet ...
Healthcare

Autologous CAR-T cell therapies: 3 ways pharma companies are addressing their manufacturing challenges

There are many challenges related to the manufacturing and supply chain needs to produce autologous CAR-T cell therapies. How do they impact delivery times and cost to the patient? How are some ...
Healthcare

CAR-NK Cell Therapy: a possible game changer in cancer treatment?

Chimeric Antigen Receptor (CAR) NK cell-based therapy has recently been drawing significant attention as a new therapeutic tool for cancer. Alcimed sheds lights upon the key privileges of CAR-NK cell ...